Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05664178 · ClinicalTrials.gov registry record · Phase 1
Remote Resistance Exercise Powering Survivors - Gastrointestinal Oncology
A Phase 1 study of Gastrointestinal Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT05664178 is a Phase 1 study of Gastrointestinal Cancer that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 100 participants, below the 232-participant average among 48 other Gastrointestinal Cancer trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05664178, a Phase 1 study of Gastrointestinal Cancer, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate a tele-resistance training exercise program for individuals undergoing chemotherapy for advanced upper gastrointestinal cancer.
Conditions Studied
Interventions
- BEHAVIORAL Tele-Resistance Training
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-02-20 |
| Est. Completion | 2026-08-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05664178
The ClinicalTrials.gov registry entry for NCT05664178 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 232-participant average among 48 other Gastrointestinal Cancer trials with a reported enrollment target (57% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastrointestinal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tele-Resistance Training is the first listed.
NCT05664178 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05664178 about?
NCT05664178 is a clinical study titled "Remote Resistance Exercise Powering Survivors - Gastrointestinal Oncology". The purpose of the study is to evaluate a tele-resistance training exercise program for individuals undergoing chemotherapy for advanced upper gastrointestinal cancer.
What is the current status of trial NCT05664178?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2023-02-20. Estimated completion is 2026-08-22.
What conditions does trial NCT05664178 study?
This clinical trial studies the following conditions: Gastrointestinal Cancer.
What interventions are being tested in trial NCT05664178?
The interventions under investigation include: Tele-Resistance Training (BEHAVIORAL).
Who is sponsoring clinical trial NCT05664178?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05664178 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
RECRUITING · Phase 1
-
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
RECRUITING · Phase 1
-
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
RECRUITING · Phase 1
-
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
RECRUITING · Phase 1
-
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.